Core Insights - CeriBell, Inc. reported a strong financial performance for Q2 2025, with total revenue reaching $21.2 million, a 38% increase from $15.3 million in Q2 2024, driven by commercial traction and account expansion [3][10] - The company is optimistic about its growth trajectory and plans to enhance its market presence and product pipeline in the second half of 2025 [2] Financial Performance - Total revenue for Q2 2025 was $21.2 million, up 38% from $15.3 million in Q2 2024, with product revenue at $15.9 million (38% increase) and subscription revenue at $5.3 million (41% increase) [3][10] - Gross profit for Q2 2025 was $18.7 million, with a gross margin of 88%, compared to $13.2 million and 86% in Q2 2024 [4][10] - Operating expenses increased by 56% to $33.6 million in Q2 2025, primarily due to investments in the commercial organization and increased headcount [5] - The net loss for Q2 2025 was $13.6 million, or $0.38 per share, compared to a net loss of $8.9 million, or $1.61 per share, in Q2 2024 [6][10] Financial Outlook - CeriBell raised its revenue guidance for the full year 2025 to a range of $85 million to $88 million, indicating a growth of approximately 30% to 34% over the previous year [7] Company Overview - CeriBell is focused on transforming the diagnosis and management of serious neurological conditions through its innovative Ceribell System, which combines portable hardware with AI-powered algorithms for rapid diagnosis and monitoring [12]
Ceribell Reports Second Quarter 2025 Financial Results